Application of mometasone spray to reduce sore throat after tracheal intubation.

BACKGROUND: Many factors in tracheal intubation lead to postoperative sore throat from mucosal injury. Mometasone furoate spray is a moderate potency corticosteroid that prevents influx of inflammatory cells into the mucosa. The present study assessed the efficacy of this drug for reducing postoperative sore throat. MATERIAL AND METHOD: A prospective, randomized, double blind, controlled study was completed Forty-two patients undergoing general surgery with general anesthesia were randomized into two groups, momethasone and NSS group sprayed at the endotracheal tube cuff vocal cords, epiglottis and pharynx at the time of tracheal intubation. All the patients were evaluated on the incidence and severity of the sore throat at first, sixth, and 24 hour after surgery. RESULTS: The sore throat after tracheal intubation was significantly less severe after momethasone spray was used than after NSS was used at first, sixth and 24 hours after surgery. The incidences of sore throat in the momethasone group were also significantly fewer than in the SS group at sixth and 24 hour post operation (20% vs. 50% and 10% vs. 40%, respectively) but at the first hour that the incidence was not significantly different (40% vs. 75%). Number needed to treat at the first hour was 2.86, sixth hour was 3.33 and 24 hour was 3.33. CONCLUSION: Application of mometasone spray reduces postoperative sore throat after tracheal intubation.

Incidence and risk factors of hypotension and bradycardia after spinal anesthesia for cesarean section.

BACKGROUND: Hypotension or bradycardia after spinal anesthesia for cesarean section remain common and are serious complications. The current study evaluated factors associated to the incidences of hypotension or bradycardia in this context. MATERIAL AND METHOD: A prospective cross sectional study from November 1, 2004 to July 31, 2005 was conducted on 722 parturients undergoing cesarean section under spinal anesthesia. T-test and Chi-square test were used in univariate analysis to compare continuous data and categorical data respectively. Multivariate logistic regression was performed on the variables hypotension (systolic pressure decrease > 30% of baseline value) and bradycardia (heart rate < 60 bpm) p-value < 0.05 was considered significant. RESULTS: Incidence of hypotension and bradycardia were 52.6% and 2.5%. The probability of hypotension increased with estimated blood loss 500-1000 mL (odds ratio [OR] = 1.86; 95% CI 1.30-2.67, p = 0.001), estimated blood loss > 1000 mL (OR = 5.31; 95% CI 1.47-19.19, p = 0.011), and analgesia level > T4 (OR = 1.94; 95% CI 1.18-3.19, p = 0.009). Hypotension occurred despite left uterine displacement (OR = 1.56; 95% CI 1.11-2.19, p = 0.01). Risk factors associated with bradycardia were adding intrathecal morphine 0.2 mg (0.2 mL) (OR = 4.61; 95% CI 1.31-16.19, p = 0.017) to local anesthetics. CONCLUSION: The present results indicated that the incidence of hypotension after spinal anesthesia for cesarean section increased with amount of estimated blood loss > 500 mL and analgesic level > T4. Adding intrathecal morphine 0.2 mg (0.2 mL) to local anesthetics increased incidence of bradycardia.

Nalbuphine versus ondansetron for prevention of intrathecal morphine-induced pruritus after cesarean delivery.

UNLABELLED: In this prospective, randomized, double-blinded study, we compared the prophylactic efficacy of nalbuphine and ondansetron for the prevention of intrathecal morphine-induced pruritus after cesarean delivery. Two-hundred-forty parturients were randomly allocated into four groups. The N-4 group, O-4 group, O-8 group, and placebo group received IV 4 mg of nalbuphine, 4 mg of ondansetron, 8 mg of ondansetron, and 4 mL of normal saline, respectively, immediately after the baby was delivered. In the postanesthesia care unit, we found that the severity of pruritus score in the four groups was significantly different (P < 0.001). The prophylactic success rate for pruritus of the N-4, O-4, O-8, and placebo groups was 20%, 13%, 12%, and 6%, respectively (P < 0.001). The pruritus score between N-4 and placebo and O-4 and placebo was significantly different (P < 0.001 and P = 0.006, respectively). Treatment for pruritus was requested by patients in 25%, 47%, 51%, and 72% of patients in the N-4, O-4, O-8, and placebo groups, respectively (P < 0.001). There were no differences among groups in nausea/vomiting score, pain score, sedation score, or shivering score at 4, 8, and 24 h after surgery. Nalbuphine and ondansetron are more effective than placebo for the prevention of intrathecal morphine-induced pruritus after cesarean delivery. IMPLICATIONS: Nalbuphine and ondansetron are more effective than placebo for the prevention of intrathecal morphine-induced pruritus after cesarean delivery.